This section highlights FDA-related milestones and regulatory updates for drugs developed by IDEAYA Biosciences (IDYA).
Over the past two years, IDEAYA Biosciences has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
Darovasertib, IDE574, IDE849, IDE034, IDE892, Darovasertib, and IDE397. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
Darovasertib FDA Regulatory Timeline and Events
Darovasertib is a drug developed by IDEAYA Biosciences for the following indication: Non-metastatic uveal melanoma (UM).
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- Darovasertib
- Announced Date:
- April 30, 2026
- Indication:
- Non-metastatic uveal melanoma (UM)
Announcement
IDEAYA Biosciences, Inc announced that the U.S. Food and Drug Administration (FDA) has agreed to review its New Drug Application (NDA) for darovasertib in combination with crizotinib (darovasertib combination) for patients with first line (1L) HLA*A2-negative metastatic uveal melanoma (mUM) under the Oncology Center of Excellence (OCE) Real-Time Oncology Review (RTOR) program.
AI Summary
IDEAYA Biosciences announced that the U.S. Food and Drug Administration has agreed to review its New Drug Application for darovasertib combined with crizotinib for first-line treatment of HLA*A2‑negative metastatic uveal melanoma under the Oncology Center of Excellence Real‑Time Oncology Review (RTOR) program. RTOR is intended to streamline and accelerate review by allowing earlier sharing of key data. IDEAYA plans to begin the RTOR submission process with a first pre‑submission in May and expects to complete the full NDA filing in the second half of 2026.
The Phase 2/3 registrational OptimUM‑02 trial of the darovasertib combination met its primary endpoint and will be presented as a late‑breaking oral presentation at ASCO 2026. IDEAYA is also studying darovasertib in HLA*A2‑positive metastatic uveal melanoma and in neoadjuvant and adjuvant settings for primary uveal melanoma.Read Announcement
- Drug:
- Darovasertib
- Announced Date:
- April 13, 2026
- Indication:
- Non-metastatic uveal melanoma (UM)
Announcement
IDEAYA Biosciences, Inc. announced positive topline results from their Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib (darovasertib combination) in patients with first-line (1L) HLA-A*A2:01-negative metastatic uveal melanoma (mUM).
AI Summary
IDEAYA Biosciences announced positive topline results from the Phase 2/3 registrational trial OptimUM-02, testing darovasertib combined with crizotinib as first-line therapy for HLA-A*02:01-negative metastatic uveal melanoma (mUM). The study showed an early trend toward improved overall survival versus the investigator’s choice treatment arm, although overall survival data are not yet mature. These findings suggest the combination could meaningfully change first-line care for this patient group that currently lacks approved options.
The darovasertib combination was generally well tolerated with a manageable safety profile consistent with prior reports. The most common Grade 3+ treatment-emergent adverse events were diarrhea, syncope, and hypotension, and treatment-related serious adverse events occurred at single-digit percentages. IDEAYA plans to target a New Drug Application submission to the U.S. FDA in the second half of 2026 and will present more detailed OptimUM-02 data at a major medical conference in 2026.
Read Announcement- Drug:
- Darovasertib
- Announced Date:
- April 10, 2026
- Indication:
- Non-metastatic uveal melanoma (UM)
Announcement
IDEAYA Biosciences, Inc. announced plans to issue a joint IDEAYA and Servier pre-market press release and host a conference call and webcast on Monday, April 13, 2026 at 8:00 a.m. ET to disclose topline results from their ongoing Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib in patients with first-line HLA*A2-negative metastatic uveal melanoma.
AI Summary
IDEAYA Biosciences and Servier will issue a joint pre-market press release and host a conference call and webcast on Monday, April 13, 2026 at 8:00 a.m. ET to disclose topline results from their ongoing Phase 2/3 registrational trial, OptimUM-02. The announcement will present primary outcome data for darovasertib given with crizotinib in patients with first-line HLA-A2–negative metastatic uveal melanoma.
OptimUM-02 is a registrational study intended to support potential regulatory filings if results are positive. Topline results will show the main efficacy and safety findings needed to evaluate the combination as a first-line treatment for this specific, molecularly defined patient group. Details will include response rates, survival measures, and safety signals.
Investor and media contact listed is Joshua Bleharski, Ph.D., Chief Financial Officer at IDEAYA. The companies will provide webcast access and the pre-market release prior to the call.
Read Announcement- Drug:
- Darovasertib
- Announced Date:
- March 22, 2026
- Indication:
- Non-metastatic uveal melanoma (UM)
Announcement
IDEAYA Biosciences, Inc. announced its participation in upcoming investor relations events and provided updated guidance related to the timing of its upcoming topline data release from the Phase 2/3 OptimUM-02 trial in first-line HLA-A2*-negative metastatic uveal melanoma.
AI Summary
IDEAYA Biosciences said it will take part in upcoming investor events to discuss progress on darovasertib and the OptimUM-02 program. The company is scheduled for a fireside chat with CEO Yujiro S. Hata at the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 12, 2026, and another fireside chat at the Stifel 2026 Targeted Oncology Virtual Forum on Tuesday, May 19, 2026, hosted by Laura Prendergast. These sessions give investors and analysts a chance to hear directly from management about clinical and commercial plans.
IDEAYA also provided updated guidance about the timing of its upcoming topline data release from the Phase 2/3 OptimUM-02 trial in first-line HLA-A2*-negative metastatic uveal melanoma. The announcement signals that timing expectations have been refined, and the company indicated it will discuss details during its investor outreach and in forthcoming communications. Investors are advised to follow the scheduled webcasts and press releases for the official topline timing and results.
Read Announcement- Drug:
- Darovasertib
- Announced Date:
- December 11, 2025
- Indication:
- Non-metastatic uveal melanoma (UM)
Announcement
IDEAYA Biosciences, Inc announced it has completed its targeted full enrollment of 435 patients in the registration-enabling Phase 2/3 trial (OptimUM-02) evaluating darovasertib, the company's investigational oral protein kinase C (PKC) inhibitor, in combination with Pfizer's crizotinib, an oral c-MET inhibitor, in first line (1L) HLA*A2-negative metastatic uveal melanoma (mUM).
AI Summary
IDEAYA Biosciences announced it completed targeted full enrollment of 435 patients in its registration‑enabling Phase 2/3 OptimUM‑02 trial. The study tests darovasertib, an oral protein kinase C (PKC) inhibitor, in combination with Pfizer’s crizotinib, an oral c‑MET inhibitor, as first‑line treatment for HLA*A2‑negative metastatic uveal melanoma.
OptimUM‑02 is a multi‑arm, multi‑stage, open‑label randomized trial comparing the combination to investigator’s choice of treatment (pembrolizumab, ipilimumab plus nivolumab, or dacarbazine). The primary endpoints are median progression‑free survival (PFS) and median overall survival (mOS). IDEAYA expects topline median PFS data in Q1 2026 to support a potential accelerated approval filing in the United States; mOS data, when available, would support a potential full approval.
Metastatic uveal melanoma is a rare, aggressive eye cancer with limited treatment options. Completing enrollment of 435 patients is a key milestone that enables potential regulatory filings if the results show meaningful benefit.
Read Announcement- Drug:
- Darovasertib
- Announced Date:
- September 8, 2025
- Indication:
- Non-metastatic uveal melanoma (UM)
Announcement
IDEAYA Biosciences, Inc. will present positive interim data at their 10-Year Anniversary R&D Day from their ongoing Phase 2 OptimUM-09 trial of darovasertib in the neoadjuvant setting for primary uveal melanoma (UM).
AI Summary
IDEAYA Biosciences will share encouraging interim results at its 10-Year Anniversary R&D Day from the ongoing Phase 2 OptimUM-09 trial of darovasertib in the neoadjuvant setting for primary uveal melanoma. In 21 patients assessed for efficacy, 76% saw at least 20% tumor shrinkage before standard plaque brachytherapy, potentially reducing the eye’s radiation exposure.
Nearly half of those patients achieved a 20% or greater drop in simulated radiation dose to key vision structures, and 86% had some reduction. Two-thirds of patients experienced improved vision, gaining a median of six letters on an eye chart. A prognostic tool also showed that 67% of patients lowered their long-term risk of severe vision loss, with 38% cutting that risk by 20% or more.
Darovasertib was generally well tolerated, with mainly mild to moderate side effects. IDEAYA plans to advance the drug into a Phase 3 registration-enabling OptimUM-10 trial in mid-2025.
Read Announcement- Drug:
- Darovasertib
- Announced Date:
- July 24, 2025
- Indication:
- Non-metastatic uveal melanoma (UM)
Announcement
IDEAYA Biosciences, Inc. announced that results from a multi-site global Phase 2 study of neoadjuvant darovasertib in primary uveal melanoma was accepted for a Proffered Paper oral presentation at the 2025 European Society of Medical Oncology (ESMO) meeting, taking place on October 17-21 in Berlin, Germany.
AI Summary
IDEAYA Biosciences announced that results from its multi-site global Phase 2 study of neoadjuvant darovasertib in primary uveal melanoma have been accepted for a Proffered Paper oral presentation at the 2025 European Society for Medical Oncology (ESMO) meeting in Berlin, October 17–21. The presentation will include data from more than 90 patients across plaque brachytherapy and enucleation-eligible cohorts, highlighting early signals of enucleation prevention and vision preservation.
Darovasertib has received U.S. FDA Breakthrough Therapy Designation for neoadjuvant use in uveal melanoma patients facing enucleation. IDEAYA’s team will discuss how darovasertib could change disease management and potentially improve outcomes in earlier-stage disease.
To build on these findings, IDEAYA plans to launch a global randomized Phase 3 registrational trial, OptimUM-10, in primary uveal melanoma in Q3 2025. The oral presenter will be Dr. Marcus Butler, MD, from the Princess Margaret Cancer Center.
Read Announcement- Drug:
- Darovasertib
- Announced Date:
- April 14, 2025
- Indication:
- Non-metastatic uveal melanoma (UM)
Announcement
IDEAYA Biosciences, Inc. announced a successful FDA Type D meeting on the Phase 3 registrational trial design that will assess the safety and efficacy of darovasertib for potential regulatory approval as neoadjuvant therapy for primary uveal melanoma (UM).
AI Summary
IDEAYA Biosciences announced a successful FDA Type D meeting regarding the design of its Phase 3 registrational trial. This trial will assess the safety and efficacy of darovasertib as neoadjuvant therapy for primary uveal melanoma (UM). The meeting provided guidance for using key clinical endpoints to secure full regulatory approval. For the enucleation-eligible cohort, the primary endpoint will focus on eye preservation rate, while for the plaque brachytherapy cohort, it will assess the proportion of patients experiencing significant vision loss. Additionally, the trial will require that darovasertib does not adversely impact event-free survival in either cohort.
The Phase 3 trial is projected to enroll about 520 patients randomized at a 2:1 ratio, and IDEAYA aims to start enrollment in the first half of 2025. The successful meeting sets a clear path for darovasertib’s development as a critical treatment option for primary UM.
Read Announcement- Drug:
- Darovasertib
- Announced Date:
- March 31, 2025
- Indication:
- Non-metastatic uveal melanoma (UM)
Announcement
IDEAYA Biosciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for darovasertib, a potential first-in-class protein kinase C (PKC) inhibitor, for the neoadjuvant treatment of adult patients with primary uveal melanoma (UM) for whom enucleation has been recommended.
AI Summary
IDEAYA Biosciences announced that the FDA has granted Breakthrough Therapy designation for its experimental drug darovasertib, a potential first-in-class protein kinase C inhibitor. This designation is for the neoadjuvant treatment of adult patients with primary uveal melanoma—a type of eye cancer—who are candidates for enucleation, or eye removal.
The FDA’s decision was supported by updated clinical data from a Phase 2 trial showing promising outcomes in reducing tumor size and preserving the eye. With no approved systemic therapies available for this condition, the Breakthrough Therapy designation is important because it allows for expedited development and priority review by the FDA. IDEAYA plans to present further Phase 2 results in 2025 and aims to initiate a Phase 3 registrational trial later next year, potentially offering a critical new treatment option for patients with uveal melanoma.
Read Announcement- Drug:
- Darovasertib
- Announced Date:
- September 23, 2024
- Indication:
- Non-metastatic uveal melanoma (UM)
Announcement
IDEAYA Biosciences, Inc
AI Summary
IDEAYA Biosciences, Inc. announced encouraging interim Phase 2 clinical data for darovasertib in neoadjuvant uveal melanoma (UM). The data showed that approximately 49% of patients experienced over 30% tumor shrinkage, with about 61% of enucleation-eligible patients preserving their eye. These results support the potential of darovasertib as a new treatment option for UM and set a promising stage for a Phase 3 registrational trial. This upcoming trial is expected to enroll around 400 patients from North America, Europe, and Australia, targeting both enucleation and plaque brachytherapy cohorts. In discussions with the FDA, the design of the registrational trial includes primary endpoints of eye preservation and time to vision loss, with efforts underway to consider overall response rate as a surrogate endpoint for earlier approval scenarios. The data highlights the potential to offer patients a treatment that may help preserve vision while effectively managing tumor size.
Read Announcement- Drug:
- Darovasertib
- Announced Date:
- September 22, 2024
- Target Action Date:
- September 23, 2024
- Indication:
- Non-metastatic uveal melanoma (UM)
Announcement
IDEAYA Biosciences, Inc. announced that the company plans to issue a pre-market press release and conduct an investor webcast on Monday, September 23, 2024, at 8:00 a.m. ET to report interim Phase 2 data for darovasertib and provide a regulatory update from FDA Type C meeting in neoadjuvant uveal melanoma (UM).
AI Summary
IDEAYA Biosciences announced that it will issue a pre-market press release and hold an investor webcast on Monday, September 23, 2024 at 8:00 a.m. ET. During this webcast, the company will share interim Phase 2 clinical data for darovasertib, a selective protein kinase C inhibitor being developed to target uveal melanoma (UM) in both its primary and metastatic forms.
The presentation will also include a regulatory update from an FDA Type C meeting focused on the drug’s use in neoadjuvant UM. The webcast will cover details such as registrational trial design based on FDA guidance, baseline characteristics, the adverse event profile, and clinical efficacy results. IDEAYA’s management, along with a key opinion leader, will participate in the webcast, providing insights into the latest developments surrounding darovasertib.
Read Announcement- Drug:
- Darovasertib
- Announced Date:
- June 3, 2024
- Indication:
- Non-metastatic uveal melanoma (UM)
Announcement
IDEAYA Biosciences, Inc announced updated clinical results from the ongoing investigator-sponsored Phase 2 trial of darovasertib, a first-in-class oral, small molecular inhibitor of protein kinase C (PKC), as neoadjuvant/adjuvant treatment in uveal melanoma (UM) and clinical update for Phase 2 company-sponsored neoadjuvant UM study.
AI Summary
IDEAYA Biosciences has shared promising clinical results from an ongoing investigator-sponsored Phase 2 trial of darovasertib—its first-in-class oral PKC inhibitor used in the neoadjuvant/adjuvant treatment of uveal melanoma (UM). In this study, 75% of the 12 enucleation patients achieved eye preservation, and 67% showed over 30% tumor shrinkage, with a median shrinkage of 47% by volume after six months of treatment.
The company also provided an update on its Phase 2 neoadjuvant UM study, which has enrolled over 40 patients. Among the eight patients treated for at least four months, a median tumor shrinkage of 72% by volume was observed, with most patients avoiding enucleation by being converted to plaque brachytherapy or external beam radiotherapy. IDEAYA plans a Type C meeting with the FDA in H2 2024 to discuss a potential registrational trial for darovasertib in this setting.
Read Announcement
IDE574 FDA Regulatory Events
IDE574 is a drug developed by IDEAYA Biosciences for the following indication: Breast and Lung Cancers.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- IDE574
- Announced Date:
- April 6, 2026
- Indication:
- Breast and Lung Cancers
Announcement
IDEAYA Biosciences, Inc announced that the first patient has been enrolled in its Phase 1 dose escalation trial evaluating IDE574, a potential first-in-class oral small molecule equipotent dual inhibitor of the lysine acetyltransferase (KAT) 6 and 7 paralogs, both of which have been shown to support cancer cell survival.
AI Summary
IDEAYA Biosciences announced that the first patient has been enrolled in its Phase 1 dose-escalation trial of IDE574. The study will gradually increase doses to evaluate safety, tolerability, drug behavior in the body, and any early signs of anti-cancer activity. This enrollment is an initial clinical milestone for the program and starts the process of identifying a dose for later studies.
IDE574 is a potential first-in-class, oral small molecule that acts as an equipotent dual inhibitor of lysine acetyltransferase (KAT) 6 and 7 paralogs—related enzymes shown to help cancer cells survive. By targeting both KAT6 and KAT7, IDEAYA aims to disrupt mechanisms that support tumor growth and persistence. The trial’s dose-escalation approach will guide whether IDE574 can move forward in development as a new targeted cancer therapy.
Read Announcement- Drug:
- IDE574
- Announced Date:
- December 10, 2025
- Target Action Date:
- Q1 2026
- Estimated Target Date Range:
- January 1, 2026 - March 31, 2026
- Indication:
- Breast and Lung Cancers
Announcement
IDEAYA Biosciences, Inc announced that the company is targeting to begin a Phase 1 dose escalation trial of monotherapy IDE574 in the first quarter of 2026.
AI Summary
IDEAYA Biosciences said it is targeting the start of a Phase 1 dose‑escalation trial of monotherapy IDE574 in the first quarter of 2026. IDE574 is a potential first‑in‑class small molecule that inhibits two epigenetic enzymes, KAT6 and KAT7, while sparing related KAT family members.
Preclinical studies show KAT6 and KAT7 work together to control lineage‑specific transcription factors that help cancer cells grow and survive. Dual KAT6/7 inhibition with IDE574 disrupted tumor lineage identity and produced strong anti‑tumor activity in patient‑derived lung and breast cancer models. IND‑enabling work supports clinical evaluation in hormone receptor‑positive breast cancer, lung adenocarcinoma, and other tumors tied to lineage addiction.
IDEAYA plans to present pharmacology and anti‑tumor preclinical data at a medical conference in the first half of 2026 and is aiming to begin the Phase 1 dose escalation in early 2026, advancing its precision oncology pipeline of targeted therapies.
Read Announcement- Drug:
- IDE574
- Announced Date:
- December 10, 2025
- Indication:
- Breast and Lung Cancers
Announcement
IDEAYA Biosciences, Inc announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for IDE574, a potential first-in-class KAT6/7 dual inhibitor with high selectivity over related KAT5/8 enzymes.
AI Summary
IDEAYA Biosciences announced it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for IDE574, a potential first‑in‑class small‑molecule dual inhibitor of KAT6 and KAT7. IDE574 is described as equipotent and highly selective, sparing related KAT5 and KAT8 enzymes. Preclinical work indicates KAT6 and KAT7 cooperate to control lineage‑specific tumor transcription factors, and that dual inhibition disrupts tumor lineage identity and reduces tumor growth in patient‑derived lung and breast cancer models.
IND‑enabling studies support clinical evaluation of IDE574 monotherapy in hormone receptor‑positive breast cancer, lung adenocarcinoma, and other cancers with lineage addiction. IDEAYA aims to start a Phase 1 dose‑escalation trial in the first quarter of 2026 and to present pharmacology and anti‑tumor preclinical data at a medical conference in the first half of 2026.
Read Announcement
IDE849 FDA Regulatory Timeline and Events
IDE849 is a drug developed by IDEAYA Biosciences for the following indication: In Solid Tumors.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- IDE849
- Announced Date:
- March 30, 2026
- Indication:
- In Solid Tumors
Announcement
IDEAYA Biosciences, Inc announced first-patient-in for a Phase 1 clinical trial combination study to evaluate IDE849, a potential first-in-class delta-like ligand 3 (DLL3)-targeting Topo-I-payload antibody drug conjugate (ADC) program, and IDE161, a potential first-in-class poly(ADP-ribose) glycohydrolase (PARG) inhibitor.
AI Summary
IDEAYA Biosciences announced the first patient has been dosed in a Phase 1 combination study testing two investigational medicines: IDE849, a potential first‑in‑class DLL3‑targeting antibody‑drug conjugate (ADC) carrying a Topo‑I payload, and IDE161, a potential first‑in‑class poly(ADP‑ribose) glycohydrolase (PARG) inhibitor. The trial will primarily evaluate safety, tolerability and dose escalation of the drug combination in patients with DLL3‑expressing solid tumors.
DLL3 is reported to be upregulated in several solid tumors—including small cell lung cancer, neuroendocrine tumors, non‑small cell lung cancer and melanoma—while showing limited expression on normal tissues. That profile makes DLL3 an attractive target for a targeted ADC like IDE849. IDE161’s PARG inhibition may complement the ADC by affecting DNA repair pathways, potentially increasing cancer cell kill.
This early study aims to assess safety and look for initial signs of clinical activity in cancers with high unmet need. Further results will determine if the combo advances to later trials.
Read Announcement- Drug:
- IDE849
- Announced Date:
- September 7, 2025
- Indication:
- In Solid Tumors
Announcement
IDEAYA Biosciences, Inc presented initial data from Hengrui's Phase 1 clinical trial of IDE849 (SHR-4849), a potential first-in-class delta-like ligand 3 (DLL3)-targeting Topoisomerase-1 (TOP1) antibody drug conjugate (ADC), in an oral presentation today at the IASLC 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
AI Summary
IDEAYA Biosciences and Hengrui Pharma presented data from a Phase 1 trial of IDE849 (SHR-4849) at the IASLC 2025 Conference on Lung Cancer in Barcelona. IDE849 is an antibody drug conjugate targeting DLL3 with a Topoisomerase 1 payload. In the expansion phase, small-cell lung cancer patients received 2.4 mg/kg every three weeks. At this dose, second-line patients showed an 80% overall response rate (ORR) and 70% confirmed ORR. Across all lines, patients achieved a 73.7% ORR and 57.9% confirmed ORR.
Patients with brain metastases had a 83.3% confirmed ORR at 2.4 mg/kg and 66.7% confirmed ORR at higher doses. Median progression-free survival was 6.7 months at doses ≥2.4 mg/kg and not yet reached in second-line patients. IDE849 showed a manageable safety profile with mostly low-grade side effects. IDEAYA and Hengrui plan to advance global development of IDE849 in SCLC and other DLL3-positive tumors.
Read Announcement- Drug:
- IDE849
- Announced Date:
- July 22, 2025
- Indication:
- In Solid Tumors
Announcement
IDEAYA Biosciences, Inc announced the publication of an abstract for an oral presentation on IDE849 (SHR-4849) at the IASLC 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (WCLC), taking place September 6-9, 2025 in Barcelona, Spain.
AI Summary
IDEAYA Biosciences, Inc. and Jiangsu Hengrui Pharmaceuticals announced the publication of an abstract for an oral presentation on IDE849 (SHR-4849) at the IASLC 2025 World Conference on Lung Cancer (WCLC), to be held September 6–9, 2025 in Barcelona, Spain. IDE849 is a potential first-in-class DLL3-targeting antibody-drug conjugate (ADC) carrying a topoisomerase-1 payload. The presentation will cover phase 1 clinical efficacy and safety data in over 70 patients with relapsed small-cell lung cancer (SCLC) from dose escalation and multiple expansion cohorts in China.
IDEAYA plans to begin a U.S. Phase 1 trial of IDE849 in SCLC patients in the third quarter of 2025. This global development effort underscores the company’s commitment to precision oncology by targeting DLL3, which is overexpressed in SCLC and other solid tumors, and aims to improve outcomes for patients facing significant unmet needs.
Read Announcement- Drug:
- IDE849
- Announced Date:
- May 6, 2025
- Indication:
- In Solid Tumors
Announcement
IDEAYA Biosciences announced the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial to evaluate IDE849 (SHR-4849), a potential first-in-class delta-like ligand 3 (DLL3)-targeting Topo-I-payload antibody drug conjugate (ADC) program, in solid tumors.
AI Summary
IDEAYA Biosciences announced that the U.S. Food and Drug Administration (FDA) has cleared their investigational new drug (IND) application, allowing them to begin a Phase 1 clinical trial for IDE849 (SHR-4849). This innovative drug is designed as a first-in-class delta-like ligand 3 (DLL3)-targeting antibody drug conjugate (ADC) with a Topo-I payload. DLL3 is found in higher levels in several solid tumors, such as small cell lung cancer (SCLC) and neuroendocrine tumors (NETs), which means IDE849 could potentially treat multiple cancer types with similar characteristics. The upcoming U.S. Phase 1 trial will study IDE849 both as a standalone treatment in various DLL3-upregulated cancers and in combination with IDE161, another experimental drug, to possibly enhance and extend treatment durability.
Read Announcement
IDE034 FDA Regulatory Timeline and Events
IDE034 is a drug developed by IDEAYA Biosciences for the following indication: First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- IDE034
- Announced Date:
- March 18, 2026
- Indication:
- First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
Announcement
IDEAYA Biosciences, Inc. announced the publication of abstracts for three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22 in San Diego, California.
AI Summary
IDEAYA Biosciences, Inc. announced the publication of abstracts for three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 17–22, 2026, in San Diego, California. The abstracts summarize research IDEAYA will present at AACR and highlight findings from its oncology programs and biomarker-driven strategies.
The poster presentations are scheduled as follows: Sunday, April 19, 2026, 2:00 PM–5:00 PM PDT; and Tuesday, April 21, 2026, 9:00 AM–12:00 PM PDT (two posters during this time slot). These posters may provide early access to data on new biomarkers, combination approaches, or clinical findings that are relevant to IDEAYA’s pipeline.
About IDEAYA: a clinical-stage precision oncology company focused on targeted therapies and synthetic lethality. For investor and media inquiries, contact Joshua Bleharski, Ph.D., Chief Financial Officer, [email protected].
Read Announcement- Drug:
- IDE034
- Announced Date:
- February 25, 2026
- Indication:
- First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
Announcement
IDEAYA Biosciences, Inc announced that the first patient has been enrolled in its Phase 1 dose escalation/expansion trial evaluating IDE034, an investigational PTK7/B7H3 bispecific TOP1 ADC.
AI Summary
IDEAYA Biosciences announced that the first patient has been enrolled in a Phase 1 dose escalation and expansion trial of IDE034, an investigational bispecific antibody‑drug conjugate that targets PTK7 and B7H3 and delivers a TOP1 cytotoxic payload. Enrolling the first patient begins human testing to assess how the drug behaves in people.
The trial will evaluate safety, tolerability and pharmacokinetics (how the drug is absorbed, distributed and cleared) and will explore IDE034 both as a standalone treatment and in combination with IDEAYA’s proprietary PARG inhibitor, IDE161. The dose escalation stage will identify safe dose levels and the expansion stage will explore activity at those doses.
PTK7 and B7H3 are reported to be co‑expressed in roughly 30–40% of several solid tumors, including lung, breast, ovarian and colorectal cancers, suggesting potential opportunities if the drug proves safe and active. The study is sponsored by IDEAYA Biosciences.
Read Announcement- Drug:
- IDE034
- Announced Date:
- December 4, 2025
- Indication:
- First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
Announcement
IDEAYA Biosciences, Inc. announced that it has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC).
AI Summary
IDEAYA Biosciences has received FDA clearance of an investigational new drug (IND) application to start a Phase 1 trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (TOP1 ADC). The company expects to begin patient enrollment in Q1 2026, initially testing IDE034 in solid tumors known to express both B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers.
IDE034 was independently developed by Biocytogen and licensed to IDEAYA in July 2024. Preclinical data showed deep, durable tumor regressions in multiple B7H3/PTK7-positive models. IDEAYA also plans combination studies with its PARG inhibitor IDE161 to try to enhance response durability and will present additional preclinical data at a major medical conference in H1 2026.
Co-expression of B7H3 and PTK7 appears in roughly 30% of lung, 46% of colorectal, and 27% of head and neck cancers, highlighting the therapy’s potential reach. Biocytogen’s discovery platforms and linker-payload technologies supported IDE034’s development.
Read Announcement- Drug:
- IDE034
- Announced Date:
- December 1, 2025
- Target Action Date:
- Q1 2026
- Estimated Target Date Range:
- January 1, 2026 - March 31, 2026
- Indication:
- First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
Announcement
IDEAYA expects to begin enrolling the study in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck and ovarian/gynecological cancers.
AI Summary
IDEAYA plans to begin enrolling a Phase 1 study in Q1 2026. The trial will initially evaluate patients with solid tumors known to express both B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. Based on the Human Protein Atlas, co-expression of B7H3 and PTK7 is reported at about 30% in lung, 46% in colorectal, and 27% in head and neck cancers.
IDE034 is a bispecific antibody‑drug conjugate that targets B7H3 and PTK7 and delivers a TOP1 cancer‑killing payload. In preclinical animal models with tumors that co‑express these markers, IDE034 produced deep and durable tumor regressions as a single agent, supporting its move into clinical testing.
Combining IDE034 with IDE161, a PARG inhibitor, enhanced durability in preclinical studies. The rationale is that TOP1 damage raises tumor reliance on PARG DNA repair, so blocking PARG may increase tumor cell death. IDEAYA plans to present additional preclinical data on this combination at a medical conference in H1 2026.
Read Announcement- Drug:
- IDE034
- Announced Date:
- December 1, 2025
- Indication:
- First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
Announcement
IDEAYA Biosciences, Inc. announced the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial to evaluate IDE034, a potential first-in-class bispecific B7H3/PTK7 TOP1 antibody-drug conjugate (ADC).
AI Summary
IDEAYA Biosciences announced FDA clearance of an investigational new drug (IND) application to begin a Phase 1 trial of IDE034, a potential first-in-class bispecific B7H3/PTK7 TOP1 antibody‑drug conjugate (ADC). The company plans to start enrolling patients in Q1 2026, initially focusing on solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers.
Based on the Human Protein Atlas, B7H3 and PTK7 are reported to be co‑expressed in about 30% of lung, 46% of colorectal, and 27% of head and neck cancers. In preclinical in vivo studies, IDE034 monotherapy produced deep and durable tumor regressions in models with B7H3/PTK7 co‑expression.
Combining IDE034 with IDEAYA’s PARG inhibitor, IDE161, improved durability in preclinical models. The company says the TOP1 payload creates replication stress that may increase reliance on the PARG pathway, supporting the rationale for the combination and plans to present more preclinical data at a medical conference in H1 2026.
Read Announcement
IDE892 FDA Regulatory Timeline and Events
IDE892 is a drug developed by IDEAYA Biosciences for the following indication: MTA-cooperative PMRT5 inhibitor.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- IDE892
- Announced Date:
- March 9, 2026
- Indication:
- MTA-cooperative PMRT5 inhibitor.
Announcement
IDEAYA Biosciences, Inc announced that the first patient has been enrolled in its Phase 1 clinical trial evaluating IDE892, an investigational MTA-cooperative PRMT5 inhibitor being developed for patients with MTAP-deleted solid tumors, including non-small cell lung cancer and pancreatic cancer.
AI Summary
IDEAYA Biosciences announced the first patient has been enrolled in a Phase 1 trial of IDE892, an investigational MTA‑cooperative PRMT5 inhibitor for patients with MTAP‑deleted solid tumors, including non‑small cell lung cancer (NSCLC) and pancreatic cancer (PDAC). The trial will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of IDE892 as a monotherapy, with plans to test a combination first patient in mid‑2026 with IDE397, a MAT2A inhibitor. Preclinical dual inhibition showed durable, well‑tolerated tumor regressions, including in NSCLC models.
IDE892 has a potential best‑in‑class profile, showing about 1,400‑fold selective binding to MTA‑PRMT5 versus SAM‑PRMT5 complexes and single‑digit nanomolar potency in MTAP‑deleted cell lines. MTAP deletion occurs in roughly 15–20% of NSCLC, up to 40% of PDAC, and about 15% of all solid tumors, often co‑deleted with CDKN2A. There are currently no approved therapies for MTAP‑deleted cancers, highlighting a significant unmet need for targeted options.
Read Announcement- Drug:
- IDE892
- Announced Date:
- September 3, 2025
- Indication:
- MTA-cooperative PMRT5 inhibitor.
Announcement
IDEAYA Biosciences, Inc. announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for IDE892, a potential best-in-class MTA-cooperative inhibitor of PRMT5.
AI Summary
IDEAYA Biosciences, Inc. announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for IDE892. IDE892 is designed as a best-in-class MTA-cooperative inhibitor of PRMT5, an enzyme involved in gene regulation. The company aims to start a Phase 1 dose-escalation trial in patients with MTAP-deleted non-small cell lung cancer in the fourth quarter of 2025.
About 15–20% of non-small cell lung cancers carry deletions in the MTAP gene, creating a unique vulnerability that IDE892 seeks to exploit. Preclinical studies show that blocking PRMT5 in these cancers disrupts tumor growth, especially when combined with IDE397, IDEAYA’s proprietary MAT2A inhibitor. IDEAYA plans to begin combination trials of IDE892 with IDE397 in the first half of 2026.
This development reflects IDEAYA’s focus on precision medicine in oncology, using targeted small molecules to address genetic drivers of cancer and improve patient outcomes.
Read Announcement- Drug:
- IDE892
- Announced Date:
- December 9, 2024
- Indication:
- MTA-cooperative PMRT5 inhibitor.
Announcement
IDEAYA Biosciences, Inc announced development candidate nomination of IDE892, a potential best-in-class MTA-cooperative PMRT5 inhibitor.
AI Summary
IDEAYA Biosciences has nominated IDE892 as a new development candidate. IDE892 is a promising best-in-class inhibitor that works by blocking PRMT5 in a way that cooperates with MTA. The drug is both potent and selective, showing favorable properties in lab tests. It has demonstrated strong anti-tumor activity, particularly in models of MTAP-deleted tumor cells, and has led to durable complete responses when used in combination with the MAT2A inhibitor IDE397.
Researchers developed IDE892 using advanced structure-based design and lead optimization techniques. The candidate meets critical target product profiles such as potency, selectivity, and synergistic combination potential. Ongoing IND-enabling studies aim to support an Investigational New Drug filing with the U.S. FDA, which is planned for mid-2025.
Read Announcement
Darovasertib + Crizotinib FDA Regulatory Events
Darovasertib + Crizotinib is a drug developed by IDEAYA Biosciences for the following indication: Metastatic uveal melanoma (MUM).
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- Darovasertib + Crizotinib
- Announced Date:
- October 20, 2025
- Indication:
- Metastatic uveal melanoma (MUM)
Announcement
IDEAYA Biosciences, Inc announced the first reported median overall survival (OS) results from their Phase 1/2 clinical trial (OptimUM-01) evaluating darovasertib, the company's investigational oral protein kinase C (PKC) inhibitor, in combination with Pfizer's crizotinib1, a c-MET inhibitor, as a first-line treatment for patients with metastatic uveal melanoma (mUM).
AI Summary
IDEAYA Biosciences reported median overall survival results from its Phase 1/2 OptimUM-01 trial of darovasertib with crizotinib as first-line treatment for metastatic uveal melanoma. The data were presented at the 2025 Society for Melanoma Research Congress.
Among 44 patients with median follow-up of 25 months, the combination achieved a median overall survival of 21.1 months versus about 12 months historically. Median progression-free survival was 7.0 months.
In 41 evaluable patients, the confirmed overall response rate was 34%, with a median duration of response of nine months. The disease control rate reached 90%, and 85% of patients saw reductions in their target lesions.
Treatment was manageable, with side effects like diarrhea, nausea, edema, vomiting, dermatitis, hypoalbuminemia, and fatigue. No grade 3 or higher treatment-related events occurred in more than 5% of patients. These results support exploring this combination as first-line therapy for uveal melanoma.
Read Announcement- Drug:
- Darovasertib + Crizotinib
- Announced Date:
- December 17, 2024
- Indication:
- Metastatic uveal melanoma (MUM)
Announcement
IDEAYA Biosciences, Inc announced the Independent Data Monitoring Committee (IDMC) recommendation of a move-forward dose and the completion of the Part 2a dose optimization consistent with the U.S. Food and Drug Administration's (FDA) Project Optimus guidelines for the potential registration-enabling Phase 2/3 trial evaluating the combination of darovasertib and crizotinib in the first-line (1L) setting in patients with HLA-A2-negative (HLA-A2(-)) metastatic uveal melanoma (MUM).
AI Summary
IDEAYA Biosciences announced that its Independent Data Monitoring Committee (IDMC) has recommended a move-forward dose and confirmed the completion of the Part 2a dose optimization for its registration-enabling Phase 2/3 trial. This trial, conducted according to the FDA’s Project Optimus guidelines, evaluates the combination of darovasertib and crizotinib as a first-line treatment for patients with HLA-A2-negative metastatic uveal melanoma (MUM). The IDMC recommendation is based on observed clinical efficacy and safety, and it marks a key milestone as the study moves from Part 2a to Part 2b. This positive step supports further enrollment and progress toward potential accelerated approval, meeting a significant need for new treatment options in a patient group with historically poor outcomes.
Read Announcement
IDE397 FDA Regulatory Timeline and Events
IDE397 is a drug developed by IDEAYA Biosciences for the following indication: Solid Tumors.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- IDE397
- Announced Date:
- September 8, 2025
- Indication:
- Solid Tumors
Announcement
IDEAYA Biosciences, Inc will present initial data at their 10-Year Anniversary R&D Day from two expansion cohorts in their Phase 1/2 combination trial of IDE397, a potential first-in-class, small molecule adenosyltransferase 2a (MAT2A) inhibitor, in combination with Gilead's Trodelvy® (sacituzumab govitecan-hziy), a Trop2-directed antibody-drug conjugate (ADC), in patients with late-line methylthioadenosine phosphorylase (MTAP)-deletion urothelial cancer (UC).
AI Summary
IDEAYA Biosciences will present initial results at its 10-Year Anniversary R&D Day from two expansion cohorts in a Phase 1/2 trial combining IDE397, a MAT2A inhibitor, with Gilead’s Trodelvy® ADC in patients with late-line MTAP-deleted urothelial cancer.
Among 16 evaluable patients, the higher dose cohort (IDE397 30 mg + Trodelvy 7.5 mg/kg) showed a 57% overall response rate (4/7: three confirmed and one unconfirmed partial responses), while the lower dose cohort (IDE397 15 mg + Trodelvy 10 mg/kg) showed a 33% response rate (3/9 confirmed responses).
The safety profile at both dose levels was manageable and consistent with known adverse events for each agent alone. No treatment-related serious adverse events were observed in the 30 mg IDE397 + 7.5 mg/kg Trodelvy expansion cohort.
IDEAYA plans to select a recommended Phase 2 dose by the end of 2025, with a further update slated for a medical conference in the first half of 2026.
Read Announcement- Drug:
- IDE397
- Announced Date:
- September 4, 2025
- Indication:
- Solid Tumors
Announcement
IDEAYA Biosciences, announced they have enrolled their first patient with non-small cell lung cancer (NSCLC) in the ongoing Phase 1/2 combination trial of IDE397, a potential first-in-class, small molecule adenosyltransferase 2a (MAT2a) inhibitor, and Trodelvy® (sacituzumab govitecan-hziy), a Trop2-directed antibody-drug conjugate (ADC), in patients with methylthioadenosine phosphorylase (MTAP)-deletion solid tumors.
AI Summary
IDEAYA Biosciences has dosed its first patient with non-small cell lung cancer (NSCLC) in an ongoing Phase 1/2 trial combining IDE397, a novel small‐molecule MAT2a inhibitor, with Trodelvy® (sacituzumab govitecan-hziy), a Trop2-targeting antibody-drug conjugate. This study focuses on solid tumors that lack the MTAP gene, which can make cancer cells more vulnerable to targeted therapy.
IDEAYA and Gilead Sciences are running the trial under a collaboration agreement that began in urothelial cancer and expanded in April 2025 to include MTAP-deleted NSCLC. Preliminary data from bladder cancer cohorts showed promise, prompting the move into lung cancer, where around 20 percent of patients carry MTAP deletions and currently have no approved targeted treatments.
By testing IDE397 alongside Trodelvy, the companies aim to exploit a synthetic-lethal approach, potentially offering a new option for patients with few alternatives. Safety and efficacy are still under evaluation, and the combination remains investigational.
Read Announcement- Drug:
- IDE397
- Announced Date:
- April 10, 2025
- Indication:
- Solid Tumors
Announcement
IDEAYA Biosciences, Inc announced the initiation of a Phase 1/2 expansion in the clinical trial evaluating IDE397, its investigational, potential first-in-class, small molecule methionine adenosyltransferase 2a (MAT2A) inhibitor, in combination with Gilead's Trodelvy® (sacituzumab govitecan-hziy), a Trop-2 directed antibody-drug conjugate (ADC), in methylthioadenosine phosphorylase (MTAP)-deletion urothelial cancer (UC) based on preliminary safety and clinical efficacy data.
AI Summary
IDEAYA Biosciences, Inc. announced the initiation of a Phase 1/2 expansion study evaluating IDE397, its investigational MAT2A inhibitor, in combination with Gilead’s Trodelvy® (sacituzumab govitecan-hziy) for patients with methylthioadenosine phosphorylase (MTAP)-deletion urothelial cancer. This combination targets a patient population with an estimated 26% prevalence of MTAP-deletion in urothelial cancer. Preliminary safety and clinical efficacy data from earlier phases support the potential of this first-in-class therapeutic approach. IDE397 is designed to inhibit MAT2A selectively in solid tumors with the MTAP deletion, addressing a significant unmet need since there are no approved therapies specifically targeting this genetic profile. The study expansion reflects IDEAYA's commitment to precision medicine by exploring novel combinations that could improve outcomes for patients with specific molecular alterations in their tumors.
Read Announcement- Drug:
- IDE397
- Announced Date:
- February 13, 2025
- Indication:
- Solid Tumors
Announcement
IDEAYA Biosciences, Inc. announced it has entered into an additional clinical study collaboration and supply agreement with Gilead Sciences, Inc. (Gilead) to evaluate the efficacy and safety of IDE397, its investigational, potential first-in-class, small molecule MAT2A inhibitor, in combination with Gilead's Trodelvy® (sacituzumab govitecan-hziy), a Trop-2 directed antibody-drug conjugate (ADC), in methylthioadenosine phosphorylase (MTAP)-deletion non-small cell lung cancer (NSCLC).
AI Summary
IDEAYA Biosciences, Inc. announced a new clinical study collaboration and supply agreement with Gilead Sciences to evaluate its investigational compound IDE397 in combination with Gilead’s Trodelvy®. IDE397 is a potential first-in-class, small molecule inhibitor of MAT2A, which is aimed at treating cancers with methylthioadenosine phosphorylase (MTAP) deletion. The trial will focus on patients with non-small cell lung cancer (NSCLC) that exhibit MTAP deletion—a mutation present in about 15% of NSCLC cases.
The study expands on current evaluations of the IDE397 and Trodelvy combination, which are already being explored in MTAP-deletion urothelial cancer. This collaborative effort retains commercial rights for each company’s compound and aims to determine the safety and effectiveness of the combination, offering a promising new approach in precision medicine for treating MTAP-deleted solid tumors.
Read Announcement- Drug:
- IDE397
- Announced Date:
- July 8, 2024
- Indication:
- Solid Tumors
Announcement
IDEAYA Biosciences, announced positive clinical data for the IDE397 Phase 2 monotherapy expansion dose in methylthioadenosine phosphorylase (MTAP)-deletion urothelial and non-small cell lung cancer (NSCLC) patients.
AI Summary
IDEAYA Biosciences announced positive Phase 2 clinical data for IDE397, a potential first-in-class MAT2A inhibitor, in patients with MTAP-deletion urothelial and non-small cell lung cancers (NSCLC). In the study, 18 evaluable patients showed promising results at a 30 mg once-daily dose. The overall response rate was 39%, with one complete response and six partial responses noted, while 94% of patients achieved disease control, including those with stable disease. Additionally, 78% of patients experienced tumor shrinkage and an 81% reduction in circulating tumor DNA (ctDNA) levels was observed. The safety profile was encouraging, with approximately 5.6% of patients experiencing grade 3 or higher adverse events and no drug-related serious adverse events or discontinuations. These findings underscore the potential of IDE397 to address the high unmet need for effective treatments in approximately 48,000 U.S. patients with MTAP-deletion solid tumors.
Read Announcement- Drug:
- IDE397
- Announced Date:
- July 5, 2024
- Target Action Date:
- July 8, 2024
- Indication:
- Solid Tumors
Announcement
IDEAYA Biosciences announced that the company plans to issue a pre-market press release and conduct an investor webcast on Monday, July 8, 2024, at 8:00 a.m. EST to provide a clinical data update for the IDE397 Phase 2 monotherapy expansion dose in MTAP-deletion urothelial and non-small cell lung cancer (NSCLC) patients.
AI Summary
IDEAYA Biosciences announced that it will issue a pre-market press release and hold an investor webcast on Monday, July 8, 2024, at 8:00 a.m. EST. During the webcast, the company will provide a clinical data update on its IDE397 Phase 2 monotherapy expansion dose, which is being tested in patients with MTAP-deletion urothelial and non-small cell lung cancer (NSCLC).
The presentation will review updated clinical data, including patient baseline characteristics, pharmacokinetics, pharmacodynamics, adverse events, and efficacy results according to RECIST 1.1 criteria. Additionally, the event will feature analyses like overall response rate, disease control, and case reports with accompanying CT-scan images. IDEAYA’s leadership team, including CEO Yujiro S. Hata, CMO Darrin Beaupre, and CSO Michael White, will discuss details during this webcast, which investors can access via the company’s Investor Relations website.
Read Announcement- Drug:
- IDE397
- Announced Date:
- June 25, 2024
- Indication:
- Solid Tumors
Announcement
IDEAYA Biosciences, Inc announced that it has dosed its first patient in the IDEAYA-sponsored Phase 1 trial evaluating the combination of IDE397, IDEAYA's investigational MAT2A inhibitor
AI Summary
IDEAYA Biosciences, Inc. has reached a significant milestone by dosing the first patient in its IDEAYA-sponsored Phase 1 trial. The trial is evaluating a new combination treatment that pairs IDE397, the company’s investigational MAT2A inhibitor, with Trodelvy®, a Trop-2 directed antibody-drug conjugate from Gilead. This study is focused on patients with MTAP-deletion bladder cancer, a group that faces a poor prognosis. Researchers will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and early efficacy of this novel combination. According to Dr. Darrin M. Beaupre, the dual-target strategy may bring first-in-class improvements by attacking cancer through two complementary mechanisms. The trial represents an important step toward developing precision therapies aimed at specific genetic features in cancer patients.
Read Announcement- Drug:
- IDE397
- Announced Date:
- June 24, 2024
- Indication:
- Solid Tumors
Announcement
IDEAYA Biosciences announced clinical program updates for IDE397, a potential first-in-class Phase 2 MAT2A inhibitor targeting MTAP-deletion solid tumors.
AI Summary
IDEAYA Biosciences has announced significant updates for its clinical program involving IDE397, a potential first-in-class Phase 2 MAT2A inhibitor designed to target MTAP-deletion solid tumors. The program focuses on treating lung and bladder cancers, with forthcoming clinical data expected in the second half of 2024 from over approximately 15 evaluable patients.
The upcoming data release will include key efficacy results, such as RECIST 1.1 waterfall plots, swim-lane analyses, and ctDNA molecular response evaluations, along with safety information detailing adverse events, pharmacokinetics, and pharmacodynamics. In addition, IDEAYA is expanding its research to include a Phase 2 monotherapy trial in MTAP-deletion bladder cancer, on top of its ongoing study in squamous lung cancer. Over 35 clinical trial sites worldwide have been activated across the U.S., Canada, Europe, and Asia Pacific to support rapid patient enrollment and further evaluate IDE397’s potential.
Read Announcement
IDE275 FDA Regulatory Events
IDE275 is a drug developed by IDEAYA Biosciences for the following indication: In MSI-High Solid Tumors.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- IDE275
- Announced Date:
- March 26, 2025
- Indication:
- In MSI-High Solid Tumors
Announcement
IDEAYA Biosciences, Inc. announced the publication of abstracts for an oral presentation in the New Drugs on the Horizon series, and three poster presentations on IDE275 (GSK959) at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois.
AI Summary
IDEAYA Biosciences, Inc. announced that it will present data on its investigational drug IDE275 (GSK959) at the AACR Annual Meeting in Chicago, Illinois, scheduled for April 25–30, 2025. The company’s plans include publishing an abstract for an oral presentation in the New Drugs on the Horizon series and delivering three poster presentations focusing on IDE275. This potential best-in-class Werner Helicase (WRN) inhibitor has demonstrated promising preclinical results in high microsatellite instability (MSI-H) solid tumors. IDE275 is currently advancing in a Phase 1 dose escalation trial and shows promise as a monotherapy agent as well as in combination with PD1 inhibitors. The presentations at AACR 2025 will highlight the drug’s selectivity and innovative binding mode, reinforcing its potential role in treating cancers including endometrial, colorectal, and gastric tumors.
Read Announcement
IDE161 FDA Regulatory Events
IDE161 is a drug developed by IDEAYA Biosciences for the following indication: PARG Inhibitor in HRD Solid Tumors.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- IDE161
- Announced Date:
- December 10, 2024
- Indication:
- PARG Inhibitor in HRD Solid Tumors
Announcement
IDEAYA Biosciences, Inc. announced that it has dosed the first patient in the IDEAYA-sponsored Phase 1 trial evaluating the combination of IDE161, the company's investigational, potential first-in-class, small molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor, in combination with Merck's (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in endometrial cancer patients with high microsatellite instability (MSI-high) and microsatellite stable(MSS).
AI Summary
IDEAYA Biosciences announced that it has dosed the first patient in its Phase 1 trial combining IDE161—its investigational, potential first-in-class PARG inhibitor—with Merck’s KEYTRUDA® (pembrolizumab) for endometrial cancer patients. The trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of this combination in patients with both high microsatellite instability (MSI-high) and microsatellite stable (MSS) tumors. With promising preclinical anti-tumor activity, IDE161 is being explored as part of a strategy to improve outcomes through rational combination therapies. The collaboration involves Merck supplying KEYTRUDA®, while both companies retain their commercial rights over their drugs. Experts expressed optimism that targeting PARG, a novel mechanism within the same pathway as PARP, could offer a breakthrough in the treatment of challenging endometrial cancer cases.
Read Announcement
